Early-stage opportunities Target markets and partners in high-growth biotech and healthcare sectors that rely on antimicrobial innovations, licensing potential or collaboration for scale, given Exoxemis’ focus on enzyme-based pathogen kill with low resistance.

Strategic partnerships Leverage relationships with research institutes, biotech startups, and contract research organizations to explore joint development, testing, and pilot programs that validate efficacy and open funding channels.

Cost-Effective validation Offer affordable pilot studies or grant-sponsored trials to demonstrate spectrum of activity and resistance profile, accelerating proof-of-concept to attract larger investors or corporate buyers.

Global expansion play Position for international market entry by aligning with distributors or regional biotech hubs, especially where antimicrobial resistance is a regulatory focus and early-stage innovations are prioritized.

Digital engagement Support outreach with technology stack insights to showcase digital presence and data-driven milestones, using targeted campaigns to attract potential collaborators, licensees, or customers seeking novel antimicrobial solutions.